Timolol
- Generic Name
- Timolol
- Brand Names
- Azarga, Betimol, Combigan, Cosopt, Duotrav, Istalol, Timoptic, Xalacom
- Drug Type
- Small Molecule
- Chemical Formula
- C13H24N4O3S
- CAS Number
- 26839-75-8
- Unique Ingredient Identifier
- 5JKY92S7BR
- Background
Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective agent for the management of conditions such as open-angle glaucoma and hypertension.
- Indication
Ophthalmic timolol is indicated for the treatment of increased intraocular pressure in patients with ocular hypertension or open-angle glaucoma. The oral form of this drug is used to treat high blood pressure. In certain cases, timolol is used in the prevention of migraine headaches.
- Associated Conditions
- Increased Intra Ocular Pressure (IOP), Migraine, Ocular Hypertension, Open Angle Glaucoma (OAG)
Safety and IOP-Lowering Effects of WB007
- Conditions
- Ocular HypertensionGlaucoma, Primary Open Angle
- Interventions
- First Posted Date
- 2019-11-04
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 77
- Registration Number
- NCT04149899
- Locations
- 🇺🇸
Eye Research Foundation, Newport Beach, California, United States
Timolol Gel for Epistaxis in Hereditary Hemorrhagic Telangiectasia
- Conditions
- Hereditary Hemorrhagic Telangiectasia
- Interventions
- Drug: Placebo Gel
- First Posted Date
- 2019-10-25
- Last Posted Date
- 2021-08-24
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 27
- Registration Number
- NCT04139018
- Locations
- 🇺🇸
Washington University, Saint Louis, Missouri, United States
Study Comparing the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density and Visual Acuity
- Conditions
- OHT - Ocular HypertensionOAG - Open-Angle Glaucoma
- Interventions
- Drug: Latanoprostene bunod 0.024% QD
- First Posted Date
- 2019-04-30
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 70
- Registration Number
- NCT03931317
- Locations
- 🇺🇸
UCSD Shiley Eye Institute, La Jolla, California, United States
Optimizing Timolol Maleate Treatment of Infantile Hemangioma by Doppler Ultrasound Examination
- Conditions
- Infantile Hemangioma
- Interventions
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2019-02-19
- Lead Sponsor
- XiaoXi Lin
- Target Recruit Count
- 150
- Registration Number
- NCT03842631
- Locations
- 🇨🇳
Shanghai Ninth People's hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
A Randomized Study Evaluating the Efficacy and Safety of Timolol Ophthalmic Solution as an Acute Treatment of Migraine
- First Posted Date
- 2019-02-11
- Last Posted Date
- 2019-07-02
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT03836664
- Locations
- 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States
A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study
- Conditions
- Glaucoma and Ocular Hypertension
- Interventions
- Drug: DE-117 Ophthalmic Solution
- First Posted Date
- 2018-10-02
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- Santen Inc.
- Target Recruit Count
- 417
- Registration Number
- NCT03691662
- Locations
- 🇺🇸
North Bay Eye Associates Inc., Petaluma, California, United States
🇺🇸East Florida Eye Institute, Stuart, Florida, United States
🇺🇸Vistar Eye Center, Roanoke, Virginia, United States
A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study
- Conditions
- Glaucoma and Ocular Hypertension
- Interventions
- Drug: DE-117 Ophthalmic Solution
- First Posted Date
- 2018-10-02
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- Santen Inc.
- Target Recruit Count
- 426
- Registration Number
- NCT03691649
- Locations
- 🇺🇸
Heart of America Eye Care, P.A., Shawnee Mission, Kansas, United States
🇺🇸Eye Associates of Fort Myers, Fort Myers, Florida, United States
🇺🇸Shettle Eye Research, Largo, Florida, United States
African Glaucoma Laser Trial
- Conditions
- Open-angle Glaucoma
- Interventions
- Procedure: Selective laser trabeculoplasty (SLT)
- First Posted Date
- 2018-08-27
- Last Posted Date
- 2021-06-21
- Lead Sponsor
- West Virginia University
- Registration Number
- NCT03648229
Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study
- Conditions
- Glaucoma; DrugsNormal Tension GlaucomaPrimary Open-angle Glaucoma
- Interventions
- First Posted Date
- 2017-10-26
- Last Posted Date
- 2020-12-31
- Lead Sponsor
- Wills Eye
- Target Recruit Count
- 35
- Registration Number
- NCT03323164
- Locations
- 🇺🇸
Glaucoma Research Center - Wills Eye Hospital, Philadelphia, Pennsylvania, United States
Beta Adrenergic Antagonist for the Healing of Chronic DFU
- Conditions
- Chronic Diabetic Foot UlcersNon Healing WoundDiabetic Neuropathic Ulcers
- Interventions
- Drug: Non biologically active gel
- First Posted Date
- 2017-09-14
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 48
- Registration Number
- NCT03282981
- Locations
- 🇺🇸
VA Northern California Health Care System, Mather, CA, Sacramento, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.